StemCells, Inc. Awarded Broad U.S. Patent Covering Expandable Liver Cells
12 oct. 2012 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Oct. 12, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced the issuance of U.S. Patent Number 8,283,164 titled "Liver engrafting cells, assays, and uses thereof."...
StemCells, Inc. Announces Simultaneous Publication of Preclinical and Clinical Results of Its Neural Stem Cells for Myelination Disorder
10 oct. 2012 14h00 HE
|
StemCells, Inc.
NEWARK, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that two papers reporting clinical and preclinical data demonstrating the therapeutic potential of the...
StemCells, Inc. Announces First Transplant of Neural Stem Cells Into Patient in Clinical Trial for Dry Age-Related Macular Degeneration
04 oct. 2012 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Oct. 4, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the first patient in its Phase I/II clinical trial in dry age-related macular degeneration (AMD) has...
StemCells, Inc. Achieves Spinal Cord Injury Milestone With First Neural Stem Cell Transplant Into Patient With Sensory Function Below the Level of Injury
27 sept. 2012 09h52 HE
|
StemCells, Inc.
NEWARK, Calif., Sept. 27, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the first patient with an incomplete spinal cord injury has been enrolled in the Company's Phase...
StemCells, Inc. to Present at Neurodegenerative Conditions Research and Development Conference
12 sept. 2012 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Sept. 12, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that President and CEO Martin McGlynn will make a presentation on the Company's programs and operations...
StemCells, Inc. Provides Additional Comments on Recent Awards From the California Institute for Regenerative Medicine
10 sept. 2012 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Martin McGlynn, President and CEO, provided additional comments about the approval of two funding...
StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease Program
06 sept. 2012 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company for...
StemCells, Inc. Reports Positive Interim Data From Spinal Cord Injury Trial
03 sept. 2012 07h00 HE
|
StemCells, Inc.
NEWARK, Calif., Sept. 3, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that interim six-month data from the first patient cohort in the Company's Phase I/II clinical trial of...
StemCells, Inc. to Announce Interim Data on Spinal Cord Injury Trial at the 2012 Annual Scientific Meeting of the International Spinal Cord Society
30 août 2012 09h58 HE
|
StemCells, Inc.
NEWARK, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that Armin Curt, MD, Professor and Chairman of the Spinal Cord Injury Center at Balgrist University...
Maxim Group Initiates Research Coverage of StemCells, Inc. With Buy Recommendation
23 août 2012 09h00 HE
|
StemCells, Inc.
NEWARK, Calif., Aug. 23, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Maxim Group LLC initiated independent research coverage on the Company with a "Buy" recommendation....